Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 10, 2001 - Issue 1
Submit an article Journal homepage
17
Views
7
CrossRef citations to date
0
Altmetric
Meeting Report

IBC’s 11th Annual International Symposium: Advances in Anticoagulant, Antithrombotic and Thrombolytic Drugs

Shaker A Mousa DuPont DuPont Pharmaceuticals Co., Wilmington, DE 19880-0400, USA
&
Jawed Fareed DuPont DuPont Pharmaceuticals Co., Wilmington, DE 19880-0400, USA
Pages 157-162 | Published online: 24 Feb 2005

Bibliography

  • QUINTON PM: Cystic fibrosis: a disease in electrolyte transport. FASEB (1990) 4:2709–2717.
  • RIORDAN JR, ROMMENS JM, KEREM B et al: Identifica-tion of the cystic fibrosis gene: cloning and characteri-zation of complementary DNA. Science (1989) 245:1066–1073.
  • •One of the classical papers describing the identification of the CFTR gene and its product.
  • ELBORN JS, SHALE DJ, BRITTON JR: Cystic fibrosis: current survival and population estimates to the year 2000. Thorax (1991) 46:881–885.
  • FRIZZELL RA: Physiology of cystic fibrosis. Physic)]. Rev. (1999) 79:S1–S255.
  • ••Collection of authoritative reviews on CFTR.
  • COLLINS FS: Cystic fibrosis: molecular biology and therapeutic implications. Science (1992) 256:774–779.
  • CARSON MR, TRAVIS SM, WELSH MJ: The two nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator (C1411) have distinct functions in controlling channel activity. J Biol. Chem. (1995) 270:1711–1717.
  • SHEPPARD DN, WELSH MJ: Structure and function of the CF1R chloride channel. Physiol. Rev. (1999) 79:S23–S45.
  • •Review on current knowledge about the structure of CFTR.
  • KOPITO RR: Biosynthesis and degradation of GEHL Physic)]. Rev. (1999) 79:S167–S173.
  • RIORDAN JR: Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein. Am. J. Hum. Genet. (1999) 64:1499–1504.
  • SKACH WR: Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator. Kidney Int. (2000) 57:825–831.
  • YANG Y, JANICH S, COHN JA, WILSON JM: The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgilysosomal compartment. Proc. Nati Acad. Sci. USA (1993) 90:9480–9484.
  • PIND S, RIORDAN JR, WILLIAMS DB: Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmem-brane conductance regulator. J Biol. Chem. (1994) 269:12784–12788.
  • LOO MA, JENSEN TJ, CUI L, HOU Y, CHANG XB, RIORDANJR: Perturbation of Hsp90 interaction with nascent C1,111 prevents its maturation and accelerates its degradation by the proteasome. EMBO J. (1998) 17:6879–6887.
  • MEACHAM GC, LU Z, KING S, SORSCHER E, TOUSSON A,CYR DM: The Hdj-2/Hsc70 chaperone pair facilitates early steps in CETI( biogenesis. EMBO J. (1999) 1 8:1492–1505.
  • CHENG SH, GREGORY RJ, MARSHALL J et al.: Defective intracellular transport and processing of CFIR is the molecular basis of most cystic fibrosis. Cell (1990) 63:827–834.
  • ••Cellular basis of defect in AF508 mutations.
  • JENSEN TJ, LOO MA, PIND S, WILLIAMS DB, GOLDBERGAL, RIORDAN JR: Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell (1995) 83:129–135.
  • WARD CL, OMURA S, KOPITO RR: Degradation of CFIRby the ubiquitin-proteasome pathway. Cell (1995) 83:121–127.
  • DENNING GM, ANDERSON MP, AMARA JF, MARSHALL J,SMITH AE, WELSH MJ: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature (1992) 358:761–764.
  • •Correction of the AF508-CFTR defect by low temperatures.
  • BROWN CR, HONG-BROWN LQ, BIWERSI J, VERKMAN AS, WELCH MJ: Chemical chaperones correct the mutant phenotype of the AF508 cystic fibrosis transmem-brane conductance regulator protein. Cell Stress Chaper-ones (1996) 1:117–125.
  • •Correction of the AF508 defect by chemical chaperones.
  • WELSH MJ, SMITH AE: Molecular mechanisms of CFIR chloride channel dysfunction in cystic fibrosis. Cell (1993) 73:1251–1254.
  • PILEWSKI JM, FRIZZELL RA: Role of CFIR in airwaydisease. Physiol. Rev. (1999) 79:S215–S255.
  • KNOWLES MR, CHURCH NL, WALTNER WE et al.: A pilotstudy of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl. J Med. (1990) 322:1189–1194.
  • •First study of long-term amiloride treatment of CF.
  • REDDY MM, LIGHT MJ, QUINTON PM: Activation of the epithelial Na + channel (ENaC) requires GEM C1 channel function. Nature (1999) 402:301–304.
  • •Important conceptual paper on relationship between Na+ and Cl- transport in epithelial cells.
  • MATSUI H, GRUBB BR, TARRAN R et al.: Evidence forpericiliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell (1998) 95:1005–1015.
  • MATSUI H, DAVIS CW, TARRAN R, BOUCHER RC: Osmoticwater permeabilities of cultured, well-differentiated normal and cystic fibrosis airway epithelia. J Clin. Invest. (2000) 105:1419–1427.
  • SMITH JJ, TRAVIS SM, GREENBERG EP, WELSH MJ: Cysticfibrosis epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell (1996) 85:229–236.
  • ZABNER J, SMITH JJ, KARP PH, WIDDICOMBE JH, WELSHMJ: Loss of CFIR chloride channels alters salt absorp-tion by cystic fibrosis airway epithelia in vitro. Mot. Cell (1998) 2:397–403.
  • WELCH WJ, BROWN CR: Influence of molecular andchemical chaperones on protein folding. Cell Stress Chaperones (1996) 1:109–115.
  • SATO S, WARD CL, KROUSE ME, WINE JJ, KOPITO RR:Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. j Biol. Chem. (1996) 271:635–638.
  • HEDA GD, MARINO CR: Surface expression of the cysticfibrosis transmembrane conductance regulator mutant AF508 is markedly upreg-ulated by combina-tion treatment with sodium butyrate and low tempera-ture. Biochem. Biophys. Res. Commun. (2000) 271:659–664.
  • CHENG SH, FANG SL, ZABNER J et al.: Functional activa-tion of the cystic fibrosis trafficking mutant AF508-CFIR by overexpression. Am. J. Physiol. (1995) 268:L615–L624.
  • RUBENSTEIN RC, EGAN MF, ZEITLIN PL: In vitro pharma-cologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing AF508-CFIR j Clin. Invest. (1997) 100:2457–2463.
  • •Use of 4-phenylbutyrate to correct the AF508 in vitro.
  • RUBENSTEIN RC, ZEITLIN PL: A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in AF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial C1(111 function. Am. J Respir. Crit. Care Med. (1998) 157:484–490.
  • •First clinical trial of 4-phenylbutyrate.
  • ILLEK B, ZHANG L, LEWIS NC, MOSS RB, DONG JY, FISCHER H: Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am. J Physiol. (1999) 277:C833–C839.
  • •Combination of 4-phenylbutyrate and genistein for treatment of CF.
  • ANDERSSON C, ROOMANS GM: Activation of AF508 CFIRin a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. Eur. Respk. J. (2000) 15:937–941.
  • RUBENSTEIN RC, ZEITLIN PL: Sodium 4-phenylbutyratedownreg-ulates Hsc70: implications for intracellular trafficking of AF508-CFIR. Am. J. Physiol. Cell Physiol (2000) 278:C259–C267.
  • •Cellular basis of action of 4-phenylbutyrate in the correction of the AF508-CFTR defect.
  • LOFFING J, MOYER BD, REYNOLDS D, STANTON BA: PBAincreases CFIR expression but at high doses inhibits Cl- secretion in Calu-3 airway epithelial cells. Am. J Physic)]. (1999) 277:L700–L708.
  • MOYER BD, LOFFING-CUENI D, LOFFING J, REYNOLDS D,STANTON BA: Butyrate increases apical membrane CFIR but reduces chloride secretion in MDCK cells. Am. J. Physic]. (1999) 277 :F271–F276.
  • MCGRATH-MORROW SA, STAHL JL: G(1) Phase growtharrest and induction of p21(Waf1/Cip1/Sdi1) in IB3-1 cells treated with 4-sodium phenylbutyrate. J. Pharmacol. Exp. Ther. (2000) 294:941–947.
  • PELIDIS MA, CARDUCCI MA, SIMONS JW: Cytotoxic effects of sodium phenylbutyrate on human neuroblastomacelllines. Intl Oncol (1998) 12:889–893.
  • ENGELHARD HH, HOMER RJ, DUNCAN HA, ROZENTAL J: Inhibitory effects of phenylbutyrate on the prolifera-tion, morphology, migration and invasiveness of malignant glioma cells. J Neurooncol. (1998) 37:97–108.
  • ZEITLIN PL: Pharmacologic restoration of AF508 CFIR-mediated chloride current. Kidney Int. (2000) 57:832–837.
  • BRADBURY NA: Focus on 'Sodium 4-phenylbutyrate downreg-ulates Hsc70: implications for intracellular trafficking of AF508-CFIR'. Am. J. Physiol. Physiol.(2000) 278:C257–C258.
  • MCPHERSON MA, DORMER RL, BRADBURY NA, DODGE JA, GOODCHILD MC: Defective beta-adrenergic secretory responses in submandibular acinar cells from cystic fibrosis patients. Lancet (1986) 2:1007–1008.
  • MILLS CL, DORIN JR, DAVIDSON DJ et al.: Decreased beta-adrenergic stimulation of glycoprotein secretion in CF mice submandibular glands: reversal by the methylx an thin e, IBMX. Biochem. Biophys. Res. Commun. (1995) 215:674–681.
  • YANG Y, DEVOR DC, ENGELHARDT JF et al.: Molecular basis of defective anion transport in Lcells expressing recombinant forms of C1,11L Hum. Mol. Genet. (1993) 2 :1253–1261.
  • GRUBB B, LAZAROWSKI E, KNOWLES M, BOUCHER R:Isobutylmethylxanthine fails to stimulate chloride secretion in cystic fibrosis airway epithelia. Am. J Respir. Cell. Mol. Biol. (1993) 8:454–460.
  • HAWS CM, NEPOMUCENO IB, KROUSE ME et al.: AF508-CFIRchannels: kinetics, activation by forskolin and potentiation by xanthines. Am. J Physiol. (1996) 270:C1544–C1555.
  • •Mechanism of activation of mutant CFTR by xanthines.
  • HE Z, RAMAN S, GUO Y, REENSTRA WW: Cystic fibrosistransmembrane conductance regulator activation by cAMP-independent mechanisms. Am. J. Physiol. (1998) 275:C958–C966.
  • CHAPPE V, METTEY Y, VIERFOND JM et al.: Structuralbasis for specificity and potency of xanthine deriva-tives as activators of the CFIR chloride channel. Br. J Pharmacol. (1998) 123:683–693.
  • •Extensive pharmacological analysis of xanthines as activa-tors of CFTR.
  • SCHULTZ BD, SINGH AK, DEVOR DC, BRIDGES RJ: Pharmacology of CFIR chloride channel activity. Physic]. Rev. (1999) 79:S109–S144.
  • ••Extensive review with new data on inhibitors and activatorsof CFTR.
  • EIDELMAN 0, GUAY-BRODER C, VAN GALEN PJ et al.: Aladenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc. Natl. Acad. ScL USA (1992) 89:5562–5566.
  • GUAY-BRODER C, JACOBSON KA, BARNOY S et al.: Alreceptor antagonist 8-cyclopenty1-1,3-dipropyl xanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator AF508 mutation. Biochemistry (1995) 34:9079–9087.
  • JACOBSON KA, GUAY-BRODER C, VAN GALEN PJ et al.:Stimulation by alkylxanthines of chloride efflux in CFPAC-1 cells does not involve Al adenosine receptors. Biochemistry (1995) 34:9088–9094.
  • •Mechanism of CPX activation of CFTR.
  • PEREIRA MM, LLOYD MILLS C, DORMER RL, MCPHERSONMA: Actions of adenosine Al and A2 receptor antago-nists on CFIR antibody-inhibited beta-adrenergic mucin secretion response. Br. J Pharmacol. (1998) 125:697–704.
  • CASAVOLA V, TURNER RJ, GUAY-BRODER C, JACOBSONKA, EIDELMAN 0, POLLARD HB: CPX, a selective Al-adenosine-receptor antagonist, regulates intracel-lular pH in cystic fibrosis cells. Am. J Physiol. (1995) 269:C226–C233.
  • COHEN BE, LEE G, JACOBSON KA et al.: 8-Cyclopenty1-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and AF508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry (1997) 36:6455–6461.
  • •Elucidation of molecular interaction between CPX and CFTR.
  • ARISPE N, MA J, JACOBSON KA, POLLARD HB: Directactivation of cystic fibrosis transmembrane conduc-tance regulator channels by 8-cyclopenty1-1,3-dipr opylx an thin e (CPX) and 1,3-dially1-8-cyclohexylxanthine (DAX). J. Biol. Chem. (1998) 273:5727–5734.
  • SRIVASTAVA M, EIDELMAN 0, POLLARD HB: Pharmaco-genomics of the cystic fibrosis transmembrane conductance regulator (CFIR) and the cystic fibrosis drug CPX using genome microarray analysis. Mol. Med. (1999) 5:753–767.
  • •Pharmacogenomic study of the effects of CPX on AF508-CFTR showing normalisation of trafficking.
  • KUNZELMANN K, BRIEL M, SCHREIBER R, RICKEN S, NITSCHKE R, GREGER R: No evidence for direct activa-tion of the cystic fibrosis transmembrane conduc-tance regulator by 8-cyclopenty1-1,3-dipropyl xanthine. Cell Physiol. Biochem. (1998) 8:185–193.
  • AKIYAMA T, ISHIDA J, NAKAGAWA S et al.: Genistein, aspecific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. (1987) 262:5592–5595.
  • OGAWARA H, AKIYAMA T, WATANABE S, ITO N, KOBORIM, SEODA Y: Inhibition of tyrosine protein kinase activity by synthetic isoflavones and flavones. Antibiot. (Tokyo) (1989) 42:340–343.
  • AKIYAMA T, OGAWARA H: Use and specificity of genistein as inhibitor of protein-tyrosine kinases. Methods Enzymol. (1991) 201:362–370.
  • MARKOVITS J, LINASSIER C, FOSSE P et al.: Inhibitoryeffects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. (1989) 49:5111–5117.
  • OSHEROFF N, CORBETT AH, ELSEA SH, WESTERGAARD M: Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differ-ences between drug classes. Cancer Chemother. Pharmacol. (1994) 34 (Suppl.):S19–S25.
  • HIGASHI K, OGAWARA H: Effects of isoflavone compounds on the activation of phospholipase C. Chem. Pharm. Bull. (Tokyo) (1992) 40:157–160.
  • OKAJIMA F, AKBAR M, ABDUL MAJID M, SHO K, TOMURA H, KONDO Y: Genistein, an inhibitor of protein tyrosine kinase, is also a competitive antagonist for P1 -purinergic (adenosine) receptor in FRTL-5 thyroid cells. Biochem. Biophys. Res. Commun. (1994) 203:1488–1495.
  • JI XD, MELMAN N, JACOBSON KA: Interactions of flavonoids and other phytochemicals with adenosine receptors. J. Med. Chem. (1996) 39:781–788.
  • MESSINA MJ, PERSKY V, SETCHELL KD, BARNES S: Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer (1994) 21:113–131.
  • MESSINA MJ: Legumes and soybeans: overview of their nutritional profiles and health effects. Am. J Clin. Nutr. (1999) 70 (Suppl. 3):4395-450S.
  • NGUYEN TD, CANADA AT, HEINTZ GG, GETTYS TVV, COHN JA: Stimulation of secretion by the T84 colonic epithelial cell line with dietary flavonols. Biochem. Pharmacol (1991) 41:1879–1886.
  • NGUYEN TD, CANADA AT: Citrus flavonoids stimulatesecretion by human colonic T84 cells. J Nutr. (1993) 123:259–268.
  • ILLEK B, FISCHER H, SANTOS GF, WIDDICOMBE JH,MACHEN TE, REENSTRA WW: cAMP-independent activa-tion of CEIR Cl channels by the tyrosine kinase inhibitor genistein. Am..] Physiol. (1995) 268:C886–C893.
  • •First paper on activation of CFTR by genistein.
  • LEHRICH RW, FORREST JN, JR.: Tyrosine phosphoryla-tion is a novel pathway for regulation of chloride secretion in shark rectal gland. Am. J Physiol. (1995) 269:F594–F600.
  • SEARS CL, FIROOZMAND F, MELLANDER A et al.:Genistein and tyrphostin 47 stimulate CEIR-mediated CE secretion in T84 cell monolayers. Am. J Physiol. (1995) 269:G874–G882.
  • DIENER M, HUG F: Modulation of Cl- secretion in ratdistal colon by genistein, a protein tyrosine kinase inhibitor. Eur.J. Pharmacol (1996) 299:161–170.
  • WEINREICH F, WOOD PG, RIORDAN JR, NAGEL G: Directaction of genistein on GEHL Pfltigers Arch. (1997) 434:484–491.
  • WANG F, ZELTWANGER S, YANG IC, NAIRN AC, HWANGTC: Actions of genistein on cystic fibrosis transmem-brane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J Gen. Physic]. (1998) 111:477–490.
  • CHIANG CE, CHEN SA, CHANG MS, UN CI, LUK HN: Genistein directly induces cardiac CETI( chloride current by a tyrosine kinase-independent and protein kinase A-independent pathway in guinea pig ventricular myocytes. Biochem. Biophys. Res. Commun. (1997) 235:74–78.
  • FRENCH PJ, BIJMAN J, BOT AG, BOOMAARS WE, SCHOLTE BJ, DE JONGE HR: Genistein activates CEIRCE channels via a tyrosine kinase- and protein phosphatase-independent mechanism. Am. J. Physiol. (1997) 273:C747–C753.
  • TILLY BC, BEZSTAROSTI K, BOOMAARS WE, MARINO CR,LAMERS JM, DE JONGE HR: Expression and regulation of chloride channels in neonatal rat cardiomyocytes. Mol. Cell. Biochem. (1996) 157:129–135.
  • ILLEK B, YANKASKAS JR, MACHEN TE: cAMP and genistein stimulate HCO3- conductance through CEIR in human airway epithelia. Am. J. Physiol. (1997) 272:L752–L761.
  • RANDAK C, AUERSWALD EA, ASSFALG-MACHLEIDT I, REENSTRA WW, MACHLEIDT W: Inhibition of ATPase, GTPase and adenylate kinase activities of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator by genistein. Biochem. J. (1999) 340:227–235.
  • HWANG TC, WANG F, YANG IC, REENSTRA WW: Genistein potentiates wild-type and AF508-GFIR channel activity. Am. J Physiol. (1997) 273:C988–C998.
  • •Activation of AF508 by genistein.
  • LEHRICH RW, ALLER SG, WEBSTER P, MARINO CR, FORREST JN, JR.: Vasoactive intestinal peptide, forskolin and genistein increase apical CFTR trafficking in the rectal gland of the spiny dogfish, Squalus acanthias. Acute regulation of CFTR trafficking in an intact epithelium. J Clin. Invest. (1998) 101:737–745.
  • YANG IC, CHENG TH, WANG F, PRICE EM, HWANG TC:Modulation of CEIR chloride channels by calyculin A and genistein. Am. J Physiol. (1997) 272:C142–C155.
  • ILLEK B, FISCHER H: Flavonoids stimulate Cl conduc-tance of human airway epithelium in vitro and in vivo. Am. J. Physic]. (1998) 275:L902–L910.
  • GODDARD CA, EVANS MJ, COLLEDGE WH: Genistein activates CEIR-mediated CE secretion in the murine trachea and colon. Am. J Physiol. Cell Physiol. (2000) 279:C383–C392.
  • DEVOR DC, BRIDGES RJ, PILEWSKI JM: Pharmacological modulation of ion transport across wild-type and AF508 CEIR-expressing human bronchial epithelia. Am. J. Physic]. Cell Physic]. (2000) 279:C461–C479.
  • LEUNG GP, WONG PY: Activation of cystic fibrosis transmembrane conductance regulator in rat epididymal epithelium by genistein. Biol. Reprod. (2000) 62:143–149.
  • LANSDELL KA, CAI Z, KIDD JF, SHEPPARD DN: Two mechanisms of genistein inhibition of cystic fibrosis transmembrane conductance regulatorchannels expressed in murine cell line. J. Physiol. (2000) 524:317–330.
  • ILLEK B, FISCHER H, MACHEN TE: Alternate stimulationof apical CFIR by genistein in epithelia. Am. J. Physiol. 1996 270:C265–C275.
  • NCI, DCPC: Clinical development plan: genistein. J. Cell.Biochem. (1996) 26S:114–126.
  • MESSINGER Y, YANISHEVSKI Y, EK 0 et al.: In vivotoxicity and pharmacokinetic features of B43 (anti-CD1 9)-genistein immunoconjugate in non-human primates. Clin. Cancer Res. (1998) 4:165–170.
  • UCKUN FM, MESSINGER Y, CHEN CL et al.: Treatment oftherapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kin as e inhibitor. Clin. Cancer Res. (1999) 5:3906–3913.
  • BERGER HA, TRAVIS SM, WELSH MJ: Regulation of thecystic fibrosis transmembrane conductance regulator channel by specific protein kinases and protein phosphatases. J Biol. Chem. (1993) 268:2037–2047.
  • REENSTRA WW, YURKO-MAURO K, DAM A, RAMAN S, SHORTEN S: CF1R chloride channel activation by genistein: the role of serine/threonine protein phosphatases. Am. J. Physiol. (1996) 271:C650–C657.
  • BECQ F, FANJUL M, MERTEN M, FIGARELLA C, HOLLANDE E, GOLA M: Possible regulation of CFIR-chloride channels by membrane-bound phosphatases in pancreatic duct cells. FEBS Lett. (1993) 327:337–342.
  • BECQ F, JENSEN TJ, CHANG XB et al.: Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc. Natl. Acad. Sci. USA (1994) 91:9160–9164.
  • BECQ F, VERRIER B, CHANG XB, RIORDAN JR, HANRAHAN JW: cAMP- and Ca2±-independent activa-tion of cystic fibrosis transmembrane conductance regulator channels by phenylimidazothiazole drugs. J Biol. Chem. (1996) 271:16171–16179.
  • FISCHER H, ILLEK B, MACHEN TE: Regulation of CFIR by protein phosphatase 2B and protein kinase C. Pfliigers Arch. (1998) 436:175–181.
  • KELLEY TJ, AL-NAKKASH L, COTTON CU, DRUMM ML: Activation of endogenous AF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J Clin. Invest. (1996) 98:513–520.
  • SMITH SN, MIDDLETON PG, CHADWICK S et al.: The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. Am. J. Respir. Cell Mol. Biol. (1999) 20:129–134.
  • OLESEN SP, MUNCH E, MOLDT P, DREJER J: Selective activation of Ca2±-dependent K+ channels by novel benzimidazolone. Eur. j Pharmacol. (1994) 251:53–59.
  • GRIBKOFF VK, CHAMPIGNY G, BARBRY P, DWORETZKY SI, MEANWELL NA, LAZDUNSKI M: The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. J. Biol. Chem. (1994) 269:10983–10986.
  • CHAMPIGNY G, IMLER JL, PUCHELLE E et al.: A change in gating mode leading to increased intrinsicchannelactivity compensates for defective processing in a cystic fibrosis mutant corresponding to a mild form of the disease. EMBO J (1995) 14:2417–2423.
  • DEVOR DC, SINGH AK, BRIDGES RJ, FRIZZELL RA: Modulation of C1 secretion by benzimidazolones. II. Coordinate regulation of apical GC1 and basolateral GK. Am J. Physiol. (1996) 271:L785–L795.
  • SINGH AK, DEVOR DC, GERLACH AC, GONDOR M, PILEWSKI JM, BRIDGES RJ: Stimulation ofsecretionby chlorzoxazone. J. Pharmacol. Exp. Ther. (2000) 292:778–787.
  • LINDEN KG, WEINSTEIN GD: Psoriasis: current perspec-tives with an emphasis on treatment. Am. J. Med. (1999) 107:595–605.
  • BICKERS DR, PATHAK MA: Psoralen pharmacology: studies on metabolism and enzyme induction. Nati Cancer Inst. Monogr. (1984) 66:77–84.
  • SZEWCYK A, DE WEILLE JR, LADZUNSKI M: 8-Methoxypsoralen blocks ATP-sensitive potassium channels and stimulates insulin release. Eur. J. Pharmacol. (1992) 216:323–326.
  • DEVOR DC, SINGH AK, BRIDGES RJ, FRIZZELL RA: Psoralens: novel modulators ofsecretion. Am. JPhysiol. (1997) 272:C976–C988.
  • BECQ F, METTEY Y, GRAY MA et al.: Development of substituted Benzo [c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. J. Biol. Chem. (1999) 274:27415–27425.
  • •A new group of activators of CFTR with possible clinical relevance.
  • BEDWELL DM, KAENJAK A, BENOS DJ et al.: Suppression of a CFIR premature stop mutation in a bronchial epithelial cell line. Nature Med. (1997) 3:1280–1284.
  • •Gentamicin can suppress stop mutations in CFTR.
  • WILSCHANSKI M, FAMINI C, BLAU H et al.: A pilot study of the effect of gentamicin on nasal potential differ-ence measurements in cystic fibrosis patients carrying stop mutations. Am. J. Respir. Crit. Care Med. (2000) 161:860–865.
  • FISCHER H, ILLEK B, MACHEN TE: The actin filament disrupter cytochalasin D activates the recombinant cystic fibrosis transmembrane conductance regulator channel in mouse 313 fibroblasts. J Physiol. (1995) 489:745–754.
  • SAMUELS J, AKSENTIJEVICH I, TOROSYAN Y et al.: Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) (1998) 77:268–297.
  • LALLEMAND JY, STOVEN V, ANNEREAU JP et al.: Induction by antitumoral drugs of proteins that functionally complement CFIR: a novel therapy for cystic fibrosis? Lancet (1997) 350:711–712.
  • SERMET-GAUDELUS I, STOVEN V, ANNEREAU JP et al: Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report. Mediators Inflamm. (1999) 8:13–15.
  • WITKO-SARSAT V, SERMET-GAUDELUS I, LENOIR G, DESCAMPS-LATSCHA B: Inflammation and GEM: might neutrophils be the key in cystic fibrosis? Mediators Inflamm. (1999) 8:7–11.
  • FRIZELL RA, RECHKEMMER G, SHOEMAKER RL: Altered regulation of airway epithelial chloride channels in cystic fibrosis. Science (1986) 233:558–560.
  • BOUCHER RC, CHENG EH, PARADISO AM, STUTTS MJ, KNOWLES MR, EARP HS: Chloride secretory response of cystic fibrosis human airway epithelia. Preservation of calcium but not protein kinase C- and A-dependent mechanisms. J. Clin. Invest. (1989) 84:1424–1431.
  • MASON SJ, PARADISO AM, BOUCHER RC: Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium. Br. J Pharmacol. (1991) 103:1649–1656.
  • COZENS AL, YEZZI MJ, CHIN L et al: Characterization of immortal cystic fibrosis tracheobronchial gland epithelial cells. Proc. Natl. Acad. Sci. USA (1992) 89:5171–5175.
  • CLARKE LL, HARLINE MC, GAWENIS LR, WALKER NM, TURNER JT, WEISMAN GA: Ex tracellular UTP stimulates electrogenic bicarbonate secretion across GEER knockout gallbladder epithelium. Am]. Physiol. Castro-intest. Liver Physiol. (2000) 279:G132–G138.
  • KNOWLES MR, CLARKE LL, BOUCHER RC: Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl. J. Med. (1991) 325:533–538.
  • •Use of nucleotides as alternative activators of chloride efflux in CF.
  • BENNET WD, OLIVIER KN, ZEMAN KL, HOHNEKER KW, BOUCHER RC, KNOWLES MR: Effect of uridine-5'-triphophate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am. J. Respir. Grit. Care Med. (1996) 153:1796–1801.
  • OLIVIER KN, BENNET WD, HOHNEKER KW et al: Acute safety and effects on mucociliary clearance of aerosol-ized uridine-5t-triphophate ± amiloride in normal human adults. Am. J. Respir. Grit. Care Med. (1996) 154:217–223.
  • GHOSAL S, TAYLOR CJ, COLLEDGE WH, RATCLIFF R, EVANS MJ: Sodium channel blockers and uridine triphosphate: effects on nasal potential difference in cystic fibrosis mice. Eur. Respir. j (2000) 15:146–150.
  • TAYLOR AL, SCHWIEBERT LM, SMITH JJ et al.: Epithelial P2X purinergic receptor channel expression and function. J Chn. Invest. (1999) 104:875–884.
  • ZHANG AL, ROOMANS GM: Regulation of intracellular calcium by extracellular nucleotides in cultured pig tracheal submucosal gland cells. Respir. Physiol. (1999) 118:237–246.
  • INGLIS SK, COLLETT A, MCALROY HL, WILSON SM, OLVER RE: Effect of luminal nucleotides on Cl- secretion and Na+ absorption in distal bronchi. Pfliigers Arch. (1999) 438:621–627.
  • •Inhibition of Na + uptake is an additional property of purinergic agonists.
  • DEVOR DC, PILEWSKI JM: UTP inhibits Na + absorption in wild-type and AF508 GEM-expressing human bronchial epithelia. Am. J. Physiol (1999) 276:C827–C837.
  • •Inhibition of Na + uptake is an additional property of purinergic agonists.
  • AGTERESCH HJ, DAGNELIE PC, VAN DEN BERG JW, WILSON JH: Adenosine triphosphate: established and potential clinical applications. Drugs (1999) 58:211–232.
  • APP EM, KING M, HELFESRIEDER R, KOHLER D, MATTHYS H: Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am. Rev. Respir. Dis. (1990) 141:605–612.
  • TOMKIEWICZ RP, APP EM, ZAYAS JG et al: Arniloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration and rheology of sputum. Am. Rev. Respir. Dis. (1993) 148:1002–1007.
  • MIDDLETON PG, GEDDES DM, ALTON EW: Effect of amiloride and saline on nasal mucociliary clearance and potential difference in cystic fibrosis and normal subjects. Thorax (1993) 48:812–816.
  • HOFMANN T, SENIER I, BITTNER P, HULS G, SCHWANDT HJ, LINDEMANN H: Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics and effect on sputum expectoration in patients with cystic fibrosis. J. Aerosol Med. (1997) 10:147–158.
  • HOFMANN T, STUTTS MJ, ZIERSCH A et al.: Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis. Am. J Respir. Grit. Care Med. (1998) 157:1844–1849.
  • •Use of the more stable amiloride analogue benzamil to inhibit Na + influx in CF airway epithelial cells.
  • KNOWLES MR, OLIVIER K, NOONE P, BOUCHER RC: Pharmacologic modulation of salt and water in the airway epithelium in cystic fibrosis. Am. J Respir. Grit. Care Med. (1995) 151:S65–S69.
  • PUCHELLE E, DE BENTZMANN S, ZAHM JM: Physical and functional properties of airway secretions in cystic fibrosis - therapeutic approaches. Respiration (1995) 62 (Suppl. 0:2–12.
  • GRAHAM A, HASANI A, ALTON EW et al.: No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur. Respir. J. (1993) 6:1243–1248.
  • BOWLER IM, KELMAN B, WORTHINGTON D et al.: Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. Arch. Dis. Child. (1995) 73:427–430.
  • PONS G, MARCHAND MC, D'ATHIS P et al.: French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Arniloride-AFLM Collaborative Study Group. Pediatr. Pulmonol. (2000) 30:25–31.
  • •Largest clinical study to date on the use of amiloride in CF.
  • BLANK U, GLANZ H, EISTERT B et al: Benzamil and mucoviscidosis. Primary culture of nasal mucosa as an electrophysiologic in vitro model. HNO (1996) 44:172–177.
  • RODGERS HC, KNOX AJ: The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis. Eur. Respir. J. (1999) 14:693–696.
  • GRUBB BR, BOUCHER RC: Effect of in vivo corticoster-oids on Na+ transport across airway epithelia. Am. J. Physiol. (1998) 275:C303–C308.
  • TROUT L, KING M, FENG W, INGLIS SK, BALLARD ST: Inhibition of airway liquid secretion and its effect on the physical properties of airway mucus. Am. J. Physiol. (1998) 274:L258–L263.
  • BALLARD ST, TROUT L, BEBOK Z, SORSCHER EJ, CREWS A: CFIR involvement in chloride, bicarbonate and liquid secretion by airway submucosal glands. Am. J. Physiol. (1999) 277:L694–L699.
  • DEVOR DC, SINGH AK, LAMBERT LC, DELUCA A, FRIZZELL RA, BRIDGES RJ: Bicarbonate and chloride secretion in Calu-3 human airway epithelial cells. J. Gen. Physiol. (1999) 113:743–760.
  • ILLEK B, TAM AW, FISCHER H, MACHEN TE: Anion selectivity of apical membrane conductance of Calu 3 human airway epithelium. Pflagers Arch. (1999) 437:812–822.
  • WHEAT VJ, SHUMAKER H, BURNHAM C, SHULL GE, YANKASKAS JR, SOLEIMANI M: GEM induces the expression of DRA along with C11HCO3- exchange activity in tracheal epithelial cells. Am. J. Physiol. Cell Physiol. (2000) 279:C62–C71.
  • •Connection between CFTR and chloride/bicarbonate exchange.
  • PRATHA VS, HOGAN DL, MARTENSSON BA, BERNARD J, ZHOU R, ISENBERG JI: Identification of transport abnormalities in duodenal mucosa and duodenal enterocytes from patients with cystic fibrosis. Gastro-enterology (2000) 118:1051–1060.
  • JIANG C, FANG SL, XIAO YF et al.: Partial restoration of cAMP-stimulated CFIR chloride channel activity in AF508 cells by deoxysperg-ualin. Am. J. Physiol. (1998) 275:C171–C178.
  • FULLER W, CUTHBERT AW: Post-translational disrup-tion of the AF508 cystic fibrosis transmembrane conductance regulator (CFIR)-molecular chaperone complex with geldanamycin stabilizes AF508 CFIR in the rabbit reticulocyte lysate. J. Biol. Chem. (2000) 48:37462–37468.
  • •Disruption of the connection between AF508-CFTR and chaperones resolves the trafficking defect in mutant CFTR.
  • PLEMPER RK, WOLF DH: Retrograde protein transloca-tion: eradication of secretory proteins in health and disease. Trends Biochem. Sci. (1999) 24:266–270.
  • STERN M, MUNKONGE FM, CAPLEN NJ et al.: Quantitative fluorescence measurements of chloride secretion in native airway epithelium from CF and non-CF subjects. Gene Ther. (1995) 2:766–774.
  • ANDERSSON C, DRAGOMIR A, HJELTE L, ROOMANS GM: Measurements of CFIR activity in nasal epithelial cells by MQAE. Proc. XIIIth Int. Cystic Fibrosis Congress (2000) 93.
  • DRAGOMIR A, ANDERSSON C, HJELTE L, ROOMANS GM: Assessment of CFIR function in nasal epithelium. Proc. XIIIth Int. Cystic Fibrosis Congress (200098.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.